DANBURY, Conn. (AP) - Mannkind Comp. says it is tripling their production of its new fast-acting inhalable insulin for diabetes at its Danbury plant.
Matt Pfeffer, the company’s chief financial officer, tells the News-Times (https://bit.ly/1b9iM1d ) the company plans to increase the production of Afrezza from one line that can make 120 million cartridges of the drug annually to three production lines during this quarter.
The company began selling Afrezza in February after several years in development. The Food and Drug Administration approved the drug last June for treating diabetes, three years after the agency first asked MannKind to run additional clinical studies on the drug.
Pfeffer says the company has been getting positive feedback and is hopeful the use of the drug will continue to grow.
Copyright © 2021 The Washington Times, LLC.